Skip to main content
Top

15-04-2024 | Computed Tomography | Kidneys, Ureters, Bladder, Retroperitoneum

Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics

Authors: Jing Xue, Zijian Zhuang, Lin Peng, Xingchi Chen, Haitao Zhu, Dongqing Wang, Lirong Zhang

Published in: Abdominal Radiology

Login to get access

Abstract

Objective

To investigate multiphase computed tomography (CT) radiomics-based combined with clinical factors to predict overall survival (OS) in patients with bladder urothelial carcinoma (BLCA) who underwent transurethral resection of bladder tumor (TURBT).

Methods

Data were retrospectively collected from 114 patients with primary BLCA from February 2016 to February 2018. The regions of interest (ROIs) of the plain, arterial, and venous phase images were manually segmented. The Cox regression algorithm was used to establish 3 basic models for the plain phase (PP), arterial phase (AP), and venous phase (VP) and 2 combination models (AP + VP and PP + AP + VP). The highest-performing radiomics model was selected to calculate the radiomics score (Rad-score), and independent risk factors affecting patients’ OS were analyzed using Cox regression. The Rad-score and clinical risk factors were combined to construct a joint model and draw a visualized nomogram.

Results

The combined model of PP + AP + VP showed the best performance with the Akaike Information Criterion (AIC) and Consistency Index (C-index) in the test group of 130.48 and 0.779, respectively. A combined model constructed with two independent risk factors (age and Ki-67 expression status) in combination with the Rad-score outperformed the radiomics model alone; AIC and C-index in the test group were 115.74 and 0.840, respectively. The calibration curves showed good agreement between the predicted probabilities of the joint model and the actual (p < 0.05). The decision curve showed that the joint model had good clinical application value within a large range of threshold probabilities.

Conclusion

This new model can be used to predict the OS of patients with BLCA who underwent TURBT.

Graphical abstract

Literature
3.
go back to reference Babjuk, M, A Bohle, M Burger, et al., EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol, 2017. 71(3): p. 447-461.CrossRefPubMed Babjuk, M, A Bohle, M Burger, et al., EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol, 2017. 71(3): p. 447-461.CrossRefPubMed
4.
go back to reference Funt, S A and J E Rosenberg, Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol, 2017. 14(4): p. 221-234.CrossRefPubMed Funt, S A and J E Rosenberg, Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol, 2017. 14(4): p. 221-234.CrossRefPubMed
5.
go back to reference Saginala, K, A Barsouk, J S Aluru, et al., Epidemiology of Bladder Cancer. Med Sci (Basel), 2020. 8(1).PubMed Saginala, K, A Barsouk, J S Aluru, et al., Epidemiology of Bladder Cancer. Med Sci (Basel), 2020. 8(1).PubMed
6.
go back to reference Tanaka, M F and G Sonpavde, Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med, 2011. 123(3): p. 43-55.CrossRefPubMed Tanaka, M F and G Sonpavde, Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med, 2011. 123(3): p. 43-55.CrossRefPubMed
7.
go back to reference Humphrey, P A, H Moch, A L Cubilla, et al., The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. European Urology, 2016. 70(1): p. 106-119.CrossRefPubMed Humphrey, P A, H Moch, A L Cubilla, et al., The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. European Urology, 2016. 70(1): p. 106-119.CrossRefPubMed
8.
go back to reference Willis, D and A M Kamat, Nonurothelial Bladder Cancer and Rare Variant Histologies. Hematology/Oncology Clinics of North America, 2015. 29(2): p. 237-252.CrossRef Willis, D and A M Kamat, Nonurothelial Bladder Cancer and Rare Variant Histologies. Hematology/Oncology Clinics of North America, 2015. 29(2): p. 237-252.CrossRef
9.
go back to reference Lenis, A T, P M Lec, K Chamie, et al., Bladder Cancer: A Review. JAMA, 2020. 324(19): p. 1980-1991.CrossRefPubMed Lenis, A T, P M Lec, K Chamie, et al., Bladder Cancer: A Review. JAMA, 2020. 324(19): p. 1980-1991.CrossRefPubMed
10.
go back to reference Guerero, D N, A Bruce, S Vayalapra, et al., Improving the Quality of Transurethral Resection of Bladder Tumour (TURBT) Operative Notes Following the European Association of Urology Guidelines: A Completed Audit Loop Study. Cureus, 2022.CrossRefPubMedPubMedCentral Guerero, D N, A Bruce, S Vayalapra, et al., Improving the Quality of Transurethral Resection of Bladder Tumour (TURBT) Operative Notes Following the European Association of Urology Guidelines: A Completed Audit Loop Study. Cureus, 2022.CrossRefPubMedPubMedCentral
11.
go back to reference Stanton, M L, L Xiao, B A Czerniak, et al., Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases. Arch Pathol Lab Med, 2013. 137(10): p. 1337-41.CrossRefPubMedPubMedCentral Stanton, M L, L Xiao, B A Czerniak, et al., Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases. Arch Pathol Lab Med, 2013. 137(10): p. 1337-41.CrossRefPubMedPubMedCentral
12.
go back to reference Quarles, J, J Richmond, V Swamy, et al., Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management. Acad Pathol, 2021. 8: p. 23742895211022256.CrossRefPubMedPubMedCentral Quarles, J, J Richmond, V Swamy, et al., Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management. Acad Pathol, 2021. 8: p. 23742895211022256.CrossRefPubMedPubMedCentral
13.
go back to reference Lopez-Beltran, A, R J Luque, J Alvarez-Kindelan, et al., Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol, 2004. 45(5): p. 606-12.CrossRefPubMed Lopez-Beltran, A, R J Luque, J Alvarez-Kindelan, et al., Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol, 2004. 45(5): p. 606-12.CrossRefPubMed
14.
go back to reference March-Villalba, J A, D Ramos-Soler, P Soriano-Sarrio, et al., Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). Urol Oncol, 2019. 37(2): p. 158-165.CrossRefPubMed March-Villalba, J A, D Ramos-Soler, P Soriano-Sarrio, et al., Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). Urol Oncol, 2019. 37(2): p. 158-165.CrossRefPubMed
15.
go back to reference Margulis, V, S F Shariat, R Ashfaq, et al., Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 2006. 12(24): p. 7369-73.CrossRefPubMed Margulis, V, S F Shariat, R Ashfaq, et al., Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 2006. 12(24): p. 7369-73.CrossRefPubMed
16.
go back to reference Yoneda, K, N Kamiya, T Utsumi, et al., Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy. Diagnostics (Basel), 2021. 11(2).CrossRefPubMedPubMedCentral Yoneda, K, N Kamiya, T Utsumi, et al., Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy. Diagnostics (Basel), 2021. 11(2).CrossRefPubMedPubMedCentral
17.
go back to reference Yurakh, A O, D Ramos, S Calabuig-Farinas, et al., Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol, 2006. 50(3): p. 506-15; discussion 515.CrossRefPubMed Yurakh, A O, D Ramos, S Calabuig-Farinas, et al., Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol, 2006. 50(3): p. 506-15; discussion 515.CrossRefPubMed
18.
go back to reference Shur, J D, S J Doran, S Kumar, et al., Radiomics in Oncology: A Practical Guide. Radiographics, 2021. 41(6): p. 1717-1732.CrossRefPubMed Shur, J D, S J Doran, S Kumar, et al., Radiomics in Oncology: A Practical Guide. Radiographics, 2021. 41(6): p. 1717-1732.CrossRefPubMed
19.
go back to reference Kozikowski, M, R Suarez-Ibarrola, R Osiecki, et al., Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 2022. 8(3): p. 728-738.CrossRefPubMed Kozikowski, M, R Suarez-Ibarrola, R Osiecki, et al., Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 2022. 8(3): p. 728-738.CrossRefPubMed
20.
go back to reference Tian, Y, Z Ma, Z Chen, et al., Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS One, 2016. 11(7): p. e0158891.CrossRefPubMedPubMedCentral Tian, Y, Z Ma, Z Chen, et al., Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS One, 2016. 11(7): p. e0158891.CrossRefPubMedPubMedCentral
21.
22.
go back to reference Bilim, V and S Hoshi, Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC). Clinical Case Reports, 2022. 10(1).CrossRefPubMedPubMedCentral Bilim, V and S Hoshi, Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC). Clinical Case Reports, 2022. 10(1).CrossRefPubMedPubMedCentral
23.
go back to reference Verghote, F, P Sargos, J P Christodouleas, et al., International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup. Practical Radiation Oncology, 2022. 12(6): p. 524-532.CrossRefPubMed Verghote, F, P Sargos, J P Christodouleas, et al., International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup. Practical Radiation Oncology, 2022. 12(6): p. 524-532.CrossRefPubMed
24.
go back to reference Letica-Kriegel, A S, A L Tin, G M Nash, et al., Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022. 48(6): p. 1427-1432.CrossRefPubMedPubMedCentral Letica-Kriegel, A S, A L Tin, G M Nash, et al., Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022. 48(6): p. 1427-1432.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang, G, L Xu, L Zhao, et al., CT-based radiomics to predict the pathological grade of bladder cancer. Eur Radiol, 2020. 30(12): p. 6749-6756.CrossRefPubMed Zhang, G, L Xu, L Zhao, et al., CT-based radiomics to predict the pathological grade of bladder cancer. Eur Radiol, 2020. 30(12): p. 6749-6756.CrossRefPubMed
26.
go back to reference Cui, Y, Z Sun, X Liu, et al., CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment. Clinical Radiology, 2022. 77(6): p. e473-e482.CrossRefPubMed Cui, Y, Z Sun, X Liu, et al., CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment. Clinical Radiology, 2022. 77(6): p. e473-e482.CrossRefPubMed
27.
go back to reference Qian, J, L Yang, S Hu, et al., Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images. Front Oncol, 2022. 12: p. 899897.CrossRefPubMedPubMedCentral Qian, J, L Yang, S Hu, et al., Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images. Front Oncol, 2022. 12: p. 899897.CrossRefPubMedPubMedCentral
28.
go back to reference Kang, M, H S Kim, C W Jeong, et al., Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Scientific Reports, 2015. 5(1).CrossRefPubMedPubMedCentral Kang, M, H S Kim, C W Jeong, et al., Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Scientific Reports, 2015. 5(1).CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics
Authors
Jing Xue
Zijian Zhuang
Lin Peng
Xingchi Chen
Haitao Zhu
Dongqing Wang
Lirong Zhang
Publication date
15-04-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04265-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.